Human VEGFR2/KDR Quantikine ELISA Kit

• Reactivity: Hu
• Applications: ELISA
• Conjugate: HRP

Human VEGFR2/KDR Quantikine ELISA Kit Summary

• Background: The Quantikine Human VEGF R2 Immunoassay is a 4.5 hour solid-phase Immunoassay designed to measure human soluble VEGF R2 in cell culture supernates, cell lysates, serum, and plasma. It contains NS0-expressed recombinant human VEGF R2/Fc Chimera and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human VEGF R2 showed linear curves that were paral...lel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human soluble VEGF R2.
  Show More
• Specificity: Natural and recombinant human VEGF R2
• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: KDR

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: Interference observed with 1 or more available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human VEGFR2/KDR Quantikine ELISA Kit

• CD309 antigen
• CD309
• EC 2.7.10
• EC 2.7.10.1
• Fetal liver kinase 1
• fetal liver kinase-1
• Flk1
• Flk-1
• FLK1tyrosine kinase growth factor receptor
• KDR
• kinase insert domain receptor (a type III receptor tyrosine kinase)
• Kinase insert domain receptor
• KRD1
• Ly73
• Protein-tyrosine kinase receptor flk-1
• soluble VEGFR2
• vascular endothelial growth factor receptor 2
• VEGF R2
• VEGFR
• VEGFR2
• VEGFR-2

Background

VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.

⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Publications for VEGFR2/KDR/Flk-1 (DVR200)(37)

Publications using DVR200

• Zarychta, E;Bielawski, K;Wrzeszcz, K;Rhone, P;Ruszkowska-Ciastek, B; Unraveling the Angiogenic Puzzle: Pre-Treatment sVEGFR1 and sVEGFR2 Levels as Promising Prognostic Indicators in Early-Stage Breast Cancer Patients International journal of molecular sciences 2023-08-31 [PMID: 37686312] (Human)
• V Rosiek, K Janas, B Kos-Kud?a Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues Biomedicines, 2023-03-10;11(3):. 2023-03-10 [PMID: 36979820] (Human)
• L Fornaro, G Musettini, P Orlandi, I Pecora, C Vivaldi, M Banchi, F Salani, E Fini, V Massa, S Catanese, F Cucchiara, M Lencioni, G Masi, E Vasile, G Bocci Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer American journal of cancer research, 2022-07-15;12(7):3347-3356. 2022-07-15 [PMID: 35968330] (Human)
• C Jiguet-Jig, S Boissonnea, E Denicolai, V Hein, R Lasseur, J Garcia, S Romain, R Appay, T Graillon, W Mason, AF Carpentier, AA Brandes, L' Ouafik, W Wick, A Baaziz, JP Gigan, RJ Argüello, D Figarella-, O Chinot, E Tabouret Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study Acta neuropathologica communications, 2022-01-03;10(1):1. 2022-01-03 [PMID: 34980260] (Human)
• L Zilberman, A Zalik, I Fugenfirov, S Shimoni, J George, S Goland Residual alterations of cardiac and endothelial function in patients who recovered from Takotsubo cardiomyopathy Clinical cardiology, 2021-05-06;0(0):. 2021-05-06 [PMID: 33955558] (Human)
• A Waszczykow, M Podgórski, M Waszczykow, Z Gerlicz-Ko, P Jurowski Matrix Metalloproteinases MMP-2 and MMP-9, Their Inhibitors TIMP-1 and TIMP-2, Vascular Endothelial Growth Factor and sVEGFR-2 as Predictive Markers of Ischemic Retinopathy in Patients with Systemic Sclerosis-Case Series Report Int J Mol Sci, 2020-11-18;21(22):. 2020-11-18 [PMID: 33218057] (Human)
• D Dong, Y Fu, F Chen, J Zhang, H Jia, J Li, H Wang, J Wen Hyperoxia sensitizes hypoxic HeLa cells to ionizing radiation by downregulating HIF?1&alpha and VEGF expression Mol Med Rep, 2020-11-20;23(1):. 2020-11-20 [PMID: 33215223] (Human)
• RC Barbara, R Piotr, B Kornel, Z El?bieta, R Danuta, N Eduardo Divergent Impact of Breast Cancer Laterality on Clinicopathological, Angiogenic, and Hemostatic Profiles: A Potential Role of Tumor Localization in Future Outcomes J Clin Med, 2020-06-02;9(6):. 2020-06-02 [PMID: 32498398] (Human)
• C Fountzilas, M Gupta, S Lee, S Krishnamur, B Estfan, K Wang, K Attwood, J Wilton, R Bies, W Bshara, R Iyer A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma Br. J. Cancer, 2020-02-10;0(0):. 2020-02-10 [PMID: 32037403] (Human)
• H Takaya, T Namisaki, M Kitade, K Kaji, K Nakanishi, Y Tsuji, N Shimozato, K Moriya, K Seki, Y Sawada, S Saikawa, S Sato, H Kawaratani, T Akahane, R Noguchi, M Matsumoto, H Yoshiji VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma BMC Gastroenterol, 2019-10-21;19(1):167. 2019-10-21 [PMID: 31638892] (Human)
• E Zarychta, P Rhone, K Bielawski, M Michalska, D Ro??, B Ruszkowska Anti-angiogenic efficacy in invasive breast carcinoma patients depends on clinicopathological determinants Adv Med Sci, 2019-02-26;64(2):216-223. 2019-02-26 [PMID: 30818220] (Human)
• J Sánchez Ra, Y Morera Día, M Bequet-Rom, F Hernández-, KH Selman-Hou, A de la Torr, ER Santiesteb, Y Martín Bau, CH Bermúdez B, J de la Torr, JV Gavilondo, M Ayala Avil Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants BMC Immunol., 2017-07-26;18(1):39. 2017-07-26 [PMID: 28747172] (Human)
• Günay Kalender Kinetics of circulating endothelial progenitor cells in patients undergoing carotid artery surgery Ther Clin Risk Manag, 2016-12-14;12(0):1841-1847. 2016-12-14 [PMID: 28008262] (Human)
• Sushil Panta Low grade inflammation inhibits VEGF induced HUVECs migration in p53 dependent manner Biochem. Biophys. Res. Commun, 2016-12-18;0(0):. 2016-12-18 [PMID: 27998768] (Human)
• Salazar R, Capdevila J, Laquente B, Manzano J, Pericay C, Villacampa M, Lopez C, Losa F, Safont M, Gomez A, Alonso V, Escudero P, Gallego J, Sastre J, Gravalos C, Biondo S, Palacios A, Aranda E A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer, 2015-02-26;15(0):60. 2015-02-26 [PMID: 25886378] (Human)
• Sallinen H, Heikura T, Koponen J, Kosma V, Heinonen S, Yla-Herttuala S, Anttila M Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer, 2014-09-23;14(0):696. 2014-09-23 [PMID: 25245329] (Human)
• Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz L, Morosi C, Crippa F, Fare E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud F, Salvioni R, Daidone M, Gianni A, Mariani L Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. Br J Cancer, 2013-11-14;110(1):26-33. 2013-11-14 [PMID: 24231947] (Human)
• Briasoulis , Evangelo, Aravantinos , Gerasimo, Kouvatseas , George, Pappas , Periklis, Biziota , Eirini, Sainis , Ioannis, Makatsoris , Thomas, Varthalitis , Ioannis, Xanthakis , Ioannis, Vassias , Antonios, Klouvas , George, Boukovinas , Ioannis, Fountzilas , George, Syrigos , Kostanti, Kalofonos , Haralamb, Samantas , Epaminon Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer, 2013-05-29;13(1):263. 2013-05-29 [PMID: 23718900] (Human)
• Abu El-Asrar , Ahmed M, Nawaz , Mohd Imt, Kangave , Dustan, Mairaj Siddiquei , Mohammed, Geboes , Karel Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy. J Diabetes Res, 2013-03-10;0(0):539658. 2013-03-10 [PMID: 23671874] (Human)
• Jurgensmeier J, Schmoll H, Robertson J, Brooks L, Taboada M, Morgan S, Wilson D, Hoff P Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer, 2013-02-28;108(6):1316-23. 2013-02-28 [PMID: 23449351] (Human)
• Somlo G, Atzori F, Strauss L, Geese W, Specht J, Gradishar W, Rybicki A, Sy O, Vahdat L, Cortes J Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clin Cancer Res, 2013-02-12;19(7):1884-93. 2013-02-12 [PMID: 23403636] (Human)
• Widemann B, Kim A, Fox E, Baruchel S, Adamson P, Ingle A, Glade Bender J, Burke M, Weigel B, Stempak D, Balis F, Blaney S A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res, 2012-09-07;18(21):6011-22. 2012-09-07 [PMID: 22962440] (Human)
• Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. Br. J. Cancer, 2012-07-17;107(4):639-45. 2012-07-17 [PMID: 22805326] (Human)
• Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, Lim HY, Kim JS, Lechuga MJ, Lanzalone S, Lin X, Faivre S Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med, 2011-07-25;9(0):120. 2011-07-25 [PMID: 21787417] (Human)
• Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kummel S Prognostic significance of angiogenic factors in uterine cervical cancer. Anticancer Res., 2011-08-01;31(8):2589-95. 2011-08-01 [PMID: 21778309] (Human)
• Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin. Cancer Res., 2011-06-20;17(15):5113-22. 2011-06-20 [PMID: 21690570] (Human)
• de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, Deangelis L, Camphausen K, Chen A, Yung W, Prados M, Wen PY, Heymach JV Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. Clin. Cancer Res., 2011-06-01;17(14):4872-4881. 2011-06-01 [PMID: 21632852] (Human)
• Loupakis F, Cremolini C, Fioravanti A Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br. J. Cancer, 2011-03-15;104(8):1262-9. 2011-03-15 [PMID: 21407216] (Human)
• Farace F, Gross-Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, Billiot F, Mauguen A, Hill C, Escudier B Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br. J. Cancer, 2011-03-08;104(7):1144-50. 2011-03-08 [PMID: 21386843] (Human)
• Konings IR, de Jonge MJ, Burger H Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. Br. J. Cancer, 2010-09-07;103(7):987-92. 2010-09-07 [PMID: 20823884] (Human)
• Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol., 2009-05-26;27(18):3027-35. 2009-05-26 [PMID: 19470923] (Human)
• Bourlev V, Iljasova N, Adamyan L, Larsson A, Olovsson M Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis. Fertil. Steril., 2009-03-25;94(1):52-7. 2009-03-25 [PMID: 19324337] (Human)
• Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol. Ther., 2008-12-02;17(2):278-84. 2008-12-02 [PMID: 19050699] (Human)
• Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol., 2008-03-17;26(11):1810-6. 2008-03-17 [PMID: 18347007] (Human)
• Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol., 2007-10-20;25(30):4793-9. 2007-10-20 [PMID: 17947727] (Human)
• Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin. Cancer Res., 2007-05-01;13(9):2643-50. 2007-05-01 [PMID: 17473195] (Human)
• Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin. Sci., 2007-01-01;112(1):51-7. 2007-01-01 [PMID: 16928195] (Human)

Bioinformatics

• Gene Symbol: KDR